[1] Yamazaki T, Joshita S, Umemura T, et al. Association ofserum autotaxin levels with liver fibrosis in patients with chronic hepatitis C. Sci Rep, 2017, 7(4):46705. [2] 吴亚平, 周冰清, 蒋蓓莉. 慢性丙型肝炎患者发生重度肝纤维化相关因素分析. 实用肝脏病杂志, 2019, 22(2):50-53. [3] Wehmeyer MH, Ingiliz P, Christensen S, et al. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol, 2018, 90(2):304-312. [4] 曹曦, 张莹, 南月敏, 等. 血清N-糖组诊断模型在丙型肝炎患者肝纤维化评价中的应用. 中华肝脏病杂志, 2020, 28(12):1023-1029. [5] Abe T, Kuroda H, Fujiwara Y, et al. Accuracy of 2D shear wave elastography in the diagnosis of liver fibrosis in patients with chronic hepatitis C. J Clin Ultrasound, 2018, 46(5):319-327. [6] Khan AJ, Saraswat VA, Ranjan P,et al. Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. J Med Virol, 2019, 91(4):659-667. [7] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版). 中华实验和临床感染病杂志(电子版), 2015, 9(5):590-607. [8] Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. Themetavir cooperative study group. Hepatology, 1996, 24(2):289-293. [9] Chen CY, Huang CF, Cheng PN, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int, 2021, 41(6):1265-1277. [10] Yan LT, Wang LL, Yao J, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Medicine (Baltimore), 2020, 99(8):e19248. [11] Kobayashi Y, Hara N, Sugimoto R, et al. Theassociations between circulating bile acids and the muscle volume in patients with non-alcoholic fatty liver disease (NAFLD). Intern Med, 2017, 56(7):755-762. [12] 刘亿军, 段舒馨, 游春芳, 等. HFE基因多态性检测判断慢性丙型肝炎患者疾病活动的价值. 实用肝脏病杂志, 2020, 23(2):49-52. [13] Sang C, Wang X, Zhou K, et al. Bileacid profiles are distinct among patients with different etiologies of chronic liver disease. J Proteome Res, 2021, 20(5):2340-2351. [14] 崔璐瑶, 苑喜微, 刘领弟, 等. 血浆GP73联合肝脏硬度检测诊断乙型和丙型肝炎患者肝纤维化临床价值分析. 实用肝脏病杂志, 2020, 23(6):809-812. [15] Mauro E, Crespo G, Montironi C, etal. Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after SVR in recurrent hepatitis C. Hepatology, 2018, 67(5):1683-1694. [16] Qiu LX, Liu YL, Lin W, et al. Liver stiffness measurement is a potent predictor of histological fibrosis regression after hepatitis C virus clearance. Eur J Gastroenterol Hepatol, 2021, 33(4):547-554. [17] 段维佳, 王晓明, 王宇, 等. FibroTouch和FibroScan检测评估慢性乙型肝炎患者肝纤维化程度的诊断价值. 中华实验和临床病毒学杂志, 2018, 32(4):399-402. [18] Barror S, Avramovic G, Oprea C, et al. HepCare Europe: a service innovation project. HepCheck: enhancing HCV identification and linkage to care for vulnerable populations through intensified outreach screening. A prospective multisite feasibility study. J Antimicrob Chemother, 2019, 74(Suppl 5):v39-v46. [19] Nabatchikova E, Abdurakhmanov D, Rozina T, et al. Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers? J Hepatol, 2020, 73(2):469-470. [20] Kamarajah SK, Chan WK, Nik Mustapha NR, et al. Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease. Hepatol Int, 2018, 12(1):44-55. |